KRAS-Targeting Drug daraxonrasib Delivers Major Survival Gain in Pancreatic Cancer
A phase trial found daraxonrasib, a pan-RAS inhibitor that targets KRAS, nearly doubles survival for patients with advanced pancreatic cancer (median ~15 months vs historically under 8). The FDA granted Breakthrough Therapy and Orphan Drug designations and expanded-access use ahead of potential full approval later in 2026. While not a cure, the drug offers meaningful survival benefit with manageable side effects, and researchers are exploring combination therapies and immunotherapy approaches.
